13 February 2016

Frontier Mining in off-take talks

20/07/10 Robert Tyerman

Kazakhstan-focused Frontier Mining is negotiating a £6 million funding with potential customers of its two million-tonne Benkala copper project.

Chairman and chief executive Erlan Sagadiev is in London discussing possible financing deals to take Benkala into production next summer and says an off-take deal, most likely with a Chinese group, is one of the options being considered.

AIM-quoted Frontier, which is merging with its 50 per cent local Benkala partner, Colville Intercorp, by granting Colville shares, argues Benkala, with a 0.55 per cent copper grade, would break even at copper prices less than a third of today's $6,600-plus a tonne. Sagadiev, an entrepreneur who built a bust dairy business into Asia Foodmaster, the continent's leading dairy products concern, points out Frontier also has several other projects in hand.

These include a potential copper deposit, with gold and molybdenum, at Baitimir, a 10,000 oz-a-year gold project at Koskuduk newly in production and Maminskoye, a gold project, where Frontier hopes to treble estimated resources from one million oz at 2.49 grammes of gold per tonne of ore to three million oz. Sagadiev says he hopes Maminskoye will start producing in 2013 with estimated production costs of $430 an ounce, against a current market price of nearly $1200 an ounce, and says the company is looking for new assets in Kazakhstan, Kyrgyzstan and Mongolia.

Sagadiev is the controlling shareholder in Frontier, which is re-domiciling itself from Delaware in the USA to the Cayman Islands, and says he is anxious to restore its former institutional following, while hinting at a first dividend in 2013 or 2014. The company lost $30.3 million (£20.2 million) last year on maiden revenues of $2.9 million, after a $25 million 'fair value adjustment' chiefly relating to outstanding loan notes, but analysts see profitability within the not-too distant future.

Floated at 15p six years ago, Frontier shares have been dismal performers. Now 5p, 1p up from their low, they value the company at £46 million and offer speculative recovery potential for the bold.

Tags: AIM, Dividend

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Gresham brings private equity expertise to small listed stocks

There are many smaller company funds out there; but the new management of Gresham House Strategic (AIM: GHS) is trying to stand out from the crowd by bringing a ‘private equity’ approach to the public market arena. For investors who supplement their own ‘DIY’ stock picking with selected funds, GHS could be an interesting option.

Diurnal to profit from orphan drugs

Drug developer Diurnal (AIM: DNL) joined AIM a couple of days before Christmas. It already has one product in final phase III clinical trials and another due to start them shortly. So revenue generation at Diurnal should be a lot closer than at many junior biotechs. If all goes according to plan lead product Infacort should hit the market in 2018.

Forbidden focuses on selling

Forbidden Technologies (AIM: FBT) has been around a long time but has failed to generate much in the way of revenues, despite having a product that sounds like it should be a winner. There were board changes last year and new CEO Aziz Musa is shifting resources towards selling and away from technological development. This has to be the right strategy and we should find out if it’s working as this year unfolds.

Wash those nits right out of your hair!

Tyratech (AIM: TYRU) offers a compelling product proposition. Controlling bugs and parasites using conventional pesticides is both harmful to the environment and ineffective. Over the years insects have built up resistance to many of the chemicals used to kill them. So Tyratech’s natural products are not only safer but also a lot more effective than the competition. 

Angling for a cancer breakthrough

Results from medical device manufacturer Angle (AIM: AGL) showed its innovative Parsortix system to be nicely on track. The first commercial sales for research use have just been made and three leading cancer centres are moving forward with trials that will support its clinical use in the diagnosis of ovarian cancer.

2016 Quoted Company Award Winners announced

The 12th annual Grant Thornton Quoted Company Awards took place this week at the Natural History Museum in London. This prestigious event is organised by Growth Company Investor and is a celebration of the success and achievements of the UK’s smaller company sector. We published the shortlisted nominees for each award category earlier in January; so read on to see who the winners were...

More News